Duopharma Biotech expects longer-term revenue recovery


KUALA LUMPUR: Duopharma Biotech Bhd is looking at a gradual recovery in revenue as it continues to strengthen its portfolio with high-value innovative offerings and niche products.

Group managing director Leonard Ariff Abdul Shatar said the group will focus on the ethical and consumer healthcare segments, while weathering persistent industry-wide challenges.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

MyBeST charges up for execution
CAB Cakaran ready to roll in Indonesia
Malaysia can rest easy for now
KSL’s quiet transformation
Gold’s shine to sustain
More turbulence ahead?
Brands set to shine at upcoming Putra Brand Awards
Yayasan Peneraju unveils new basic package to accelerate Bumiputera AI upskilling
DIY homes: A growing trend
Why speculation hurts homebuyers

Others Also Read